Microbix expands QAPs portfolio with new PCR-test control
04 January 2022
Microbix Biosystems has expanded its Quality Assessment Products (QAPs) portfolio with the introduction of the new Multiplex Respiratory PCR-Test Control.
The single-unit swab-formatted test control is designed to support PCR tests for four most-common global viral infectious respiratory illness, SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B), and Respiratory Syncytial Virus (RSV).
The company stated that the in-vitro diagnostic (IVD) quality controls can improve the workflow accuracy of multiplex clinical laboratory PCR lab tests, which can detect Flu A, Flu B, SARS-CoV-2, and RSV using a single sample.
Developed using COPAN FLOQSwabs, the Microbix multiplex QAP is branded as REDx FLOQ SARS-CoV-2/Flu A&B/RSV Swab Positive Control.
It comprises all possible PCR targets and uses multiple test platforms.
Currently, the new QAP is available to support quality management systems (QMS) of clinical laboratory that include point-of care workflows and central lab in Canada and the US.
Microbix CEO and president Cameron Groome said: “For optimal patient care and public health management, clinicians and lab directors are rapidly moving to tests that can detect multiple infectious organisms from a single patient-sample.
“Microbix is therefore applying its expertise to develop the leading-edge “multiplex” test controls required to enable and accelerate this very positive evolution.
“I encourage clinical lab directors to reach out to Microbix or one of our nine distributors to sample these important new products for optimally-ensuring the quality of multiplex PCR-tests for respiratory viruses.”
Now, the company’s QAPs portfolio of more than 70 proprietary SKUs, of which 16 QAPs are available as REDx Controls for IVD.
Do you want to contribute to the research and development by joining a Life Science organisation specialised in Medical Devices? Check out our available opportunities here!
Also published on Medicaldevice-network.com